MiRNA-mediated silencing in hepatocytes can increase adaptive immune responses to adenovirus vector-delivered transgenic antigens

Molecular Therapy

Volumn 19, Issue 8, 2011, Pages 1547-1557

  Kron, Matthias W ^a   Espenlaub, Sigrid ^a   Engler, Tatjana ^a   Schirmbeck, Reinhold ^b   Kochanek, Stefan ^a   Kreppel, Florian ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MICRORNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE SILENCING; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PLASMID; REGULATORY MECHANISM; SKELETAL MUSCLE;

ADENOVIRIDAE;

EID: 79961021005     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.83     Document Type: Article

References (50)

1. Lasaro, MO and Ertl, HC (2009). New insights on adenovirus as vaccine vectors. Mol Ther 17: 1333-1339.
2. Gray, G, Buchbinder, S and Duerr, A (2010). Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5: 357-361.
3. Sekaly, RP (2008). The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
4. Bergelson, JM, Cunningham, JA, Droguett, G, Kurt-Jones, EA, Krithivas, A, Hong, JS et al. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275: 1320-1323. (Pubitemid 27114163)
5. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73: 309-319. (Pubitemid 23123309)
6. Waddington, SN, McVey, JH, Bhella, D, Parker, AL, Barker, K, Atoda, H et al. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132: 397-409. (Pubitemid 351200513)
7. Yang, HS, Lee, H, Kim, SJ, Lee, WW, Yang, YJ, Moon, DH et al. (2004). Imaging of human sodium-iodide symporter gene expression mediated by recombinant adenovirus in skeletal muscle of living rats. Eur J Nucl Med Mol Imaging 31: 1304-1311. (Pubitemid 39222495)
8. Vajanto, I, Rissanen, TT, Rutanen, J, Hiltunen, MO, Tuomisto, TT, Arve, K et al. (2002). Evaluation of angiogenesis and side effects in ischemic rabbit hindlimbs after intramuscular injection of adenoviral vectors encoding VEGF and LacZ. J Gene Med 4: 371-380. (Pubitemid 40277174)
9. De Geest, BR, Van Linthout, SA and Collen, D (2003). Humoral immune response in mice against a circulating antigen induced by adenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 101: 2551-2556. (Pubitemid 36857612)
10. Mercier, S, Gahéry-Segard, H, Monteil, M, Lengagne, R, Guillet, JG, Eloit, M et al. (2002). Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol 76: 2899-2911. (Pubitemid 34184876)
11. Lindsay, RW, Darrah, PA, Quinn, KM, Wille-Reece, U, Mattei, LM, Iwasaki, A et al. (2010). CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling. J Immunol 185: 1513-1521.
12. Bassett, JD, Yang, TC, Bernard, D, Millar, JB, Swift, SL, McGray, AJ et al. CD8+ T cell expansion and maintenance following recombinant adenovirus immunization rely upon co-operation between hematopoietic and non-hematopoietic antigenpresenting cells. Blood 117(4): 1146-1155.
13. Steitz, J, Wagner, RA, Bristol, T, Gao, W, Donis, RO and Gambotto, A (2010). Assessment of route of administration and dose escalation for an adenovirus-based influenza A Virus (H5N1) vaccine in chickens. Clin Vaccine Immunol 17: 1467-1472.
14. Sharpe, S, Fooks, A, Lee, J, Hayes, K, Clegg, C and Cranage, M (2002). Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 293: 210-216.
15. Croyle, MA, Patel, A, Tran, KN, Gray, M, Zhang, Y, Strong, JE et al. (2008). Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS ONE 3: e3548.
16. Brown, BD, Gentner, B, Cantore, A, Colleoni, S, Amendola, M, Zingale, A et al. (2007). Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state. Nat Biotechnol 25: 1457-1467. (Pubitemid 350233144)
17. Suzuki, T, Sakurai, F, Nakamura, S, Kouyama, E, Kawabata, K, Kondoh, M et al. (2008). miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther 16: 1719-1726.
18. Cawood, R, Chen, HH, Carroll, F, Bazan-Peregrino, M, van Rooijen, N and Seymour, LW (2009). Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells. PLoS Pathog 5: e1000440.
19. Ylösmäki, E, Hakkarainen, T, Hemminki, A, Visakorpi, T, Andino, R and Saksela, K (2008). Generation of a conditionally replicating adenovirus based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 82: 11009-11015.
20. Brown, BD, Venneri, MA, Zingale, A, Sergi Sergi, L and Naldini, L (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591.
21. Chang, J, Nicolas, E, Marks, D, Sander, C, Lerro, A, Buendia, MA et al. (2004). miR- 122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 1: 106-113.
22. Chen, CZ, Li, L, Lodish, HF and Bartel, DP (2004). MicroRNAs modulate hematopoietic lineage differentiation. Science 303: 83-86. (Pubitemid 38055775)
23. McCarthy, JJ (2008). MicroRNA-206: the skeletal muscle-specific myomiR. Biochim Biophys Acta 1779: 682-691.
24. Whalen, RG, Leclerc, C, Dériaud, E, Schirmbeck, R, Reimann, J and Davis, HL (1995). DNA-mediated immunization to the hepatitis B surface antigen. Activation and entrainment of the immune response. Ann N Y Acad Sci 772: 64-76. (Pubitemid 26078766)
25. Schirmbeck, R, Stober, D, El-Kholy, S, Riedl, P and Reimann, J (2002). The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes. J Immunol 168: 6253-6262. (Pubitemid 34620045)
26. Schirmbeck, R, Reimann, J, Kochanek, S and Kreppel, F (2008). The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vectorencoded transgenic antigens. Mol Ther 16: 1609-1616.
27. Annoni, A, Brown, BD, Cantore, A, Sergi, LS, Naldini, L and Roncarolo, MG (2009). In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance. Blood 114: 5152-5161.
28. Ophorst, OJ, Radosevic, K, Havenga, MJ, Pau, MG, Holterman, L, Berkhout, B et al. (2006). Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 74: 313-320. (Pubitemid 43023087)
29. Brown, BD, Cantore, A, Annoni, A, Sergi, LS, Lombardo, A, Della Valle, P et al. (2007). A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice. Blood 110: 4144-4152. (Pubitemid 351377775)
30. Prasad, SA, Norbury, CC, Chen, W, Bennink, JR and Yewdell, JW (2001). Cutting edge: recombinant adenoviruses induce CD8 T cell responses to an inserted protein whose expression is limited to nonimmune cells. J Immunol 166: 4809-4812. (Pubitemid 32280685)
31. Sarukhan, A, Camugli, S, Gjata, B, von Boehmer, H, Danos, O and Jooss, K (2001). Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J Virol 75: 269-277.
32. Jooss, K, Yang, Y, Fisher, KJ and Wilson, JM (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 72: 4212-4223. (Pubitemid 28188726)
33. Brandão, JG, Scheper, RJ, Lougheed, SM, Curiel, DT, Tillman, BW, Gerritsen, WR et al. (2003). CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 21: 2268-2272. (Pubitemid 36561319)
34. Rea, D, Havenga, MJ, van Den Assem, M, Sutmuller, RP, Lemckert, A, Hoeben, RC et al. (2001). Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J Immunol 166: 5236-5244. (Pubitemid 32280740)
35. Worgall, S, Busch, A, Rivara, M, Bonnyay, D, Leopold, PL, Merritt, R et al. (2004). Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 78: 2572-2580. (Pubitemid 38228952)
36. Cao, B, Bruder, J, Kovesdi, I and Huard, J (2004). Muscle stem cells can act as antigenpresenting cells: implication for gene therapy. Gene Ther 11: 1321-1330. (Pubitemid 39213997)
37. Wolff, LJ, Wolff, JA and Sebestyén, MG (2009). Effect of tissue-specific promoters and microRNA recognition elements on stability of transgene expression after hydrodynamic naked plasmid DNA delivery. Hum Gene Ther 20: 374-388.
38. Knolle, PA and Gerken, G (2000). Local control of the immune response in the liver. Immunol Rev 174: 21-34. (Pubitemid 30201376)
39. Hoffman, BE, Dobrzynski, E, Wang, L, Hirao, L, Mingozzi, F, Cao, O et al. (2007). Muscle as a target for supplementary factor IX gene transfer. Hum Gene Ther 18: 603-613. (Pubitemid 47187092)
40. Cao, O, Dobrzynski, E, Wang, L, Nayak, S, Mingle, B, Terhorst, C et al. (2007). Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110: 1132-1140. (Pubitemid 47281408)
41. Follenzi, A, Battaglia, M, Lombardo, A, Annoni, A, Roncarolo, MG and Naldini, L (2004). Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood 103: 3700-3709. (Pubitemid 38596285)
42. Fields, PA, Armstrong, E, Hagstrom, JN, Arruda, VR, Murphy, ML, Farrell, JP et al. (2001). Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice. Gene Ther 8: 354-361. (Pubitemid 32243465)
43. Pastore, L, Morral, N, Zhou, H, Garcia, R, Parks, RJ, Kochanek, S et al. (1999). Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors. Hum Gene Ther 10: 1773-1781. (Pubitemid 29357683)
44. Krebs, P, Scandella, E, Odermatt, B and Ludewig, B (2005). Rapid functional exhaustion and deletion of CTL following immunization with recombinant adenovirus. J Immunol 174: 4559-4566.
45. Holst, PJ, Ørskov, C, Thomsen, AR and Christensen, JP (2010). Quality of the transgene-specific CD8+ T cell response induced by adenoviral vector immunization is critically influenced by virus dose and route of vaccination. J Immunol 184: 4431-4439.
46. Wortmann, A, Vöhringer, S, Engler, T, Corjon, S, Schirmbeck, R, Reimann, J et al. (2008). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol Ther 16: 154-162.
47. Schirmbeck, R, Wild, J, Stober, D, Blum, HE, Chisari, FV, Geissler, M et al. (2000). Ongoing murine T1 or T2 immune responses to the hepatitis B surface antigen are excluded from the liver that expresses transgene-encoded hepatitis B surface antigen. J Immunol 164: 4235-4243. (Pubitemid 30215083)
48. Schiedner, G, Hertel, S and Kochanek, S (2000). Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 11: 2105-2116.
49. Kreppel, F, Biermann, V, Kochanek, S and Schiedner, G (2002). A DNA-based method to assay total and infectious particle contents and helper virus contamination in high-capacity adenoviral vector preparations. Hum Gene Ther 13: 1151-1156. (Pubitemid 34746695)
50. Prill, JM, Espenlaub, S, Samen, U, Engler, T, Schmidt, E, Vetrini, F et al. (2011). Modifications of adenovirus hexon allow for either hepatocyte detargeting or targeting with potential evasion from Kupffer cells. Mol Ther 19: 83-92.